查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847670

藥物釋放型支架市場（按類型、藥物、應用、最終用戶和分銷管道）—全球預測 2025-2032

Drug Eluting Stent Market by Type, Drug, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年藥物釋放型支架市場規模將成長至 187.6 億美元，複合年成長率為 11.15%。

主要市場統計數據
基準年2024年 80.5億美元
預計2025年 89.3億美元
預測年份：2032年 187.6億美元
複合年成長率（%） 11.15%

全面介紹藥物釋放型支架的臨床相關性、設備演變、監管途徑和策略要點

藥物釋放型支架已成為介入性心臟病學和血管醫學的關鍵治療性介入，並被納入多種動脈粥狀硬化疾病的現代治療途徑。在過去的二十年中，這些裝置已從第一代設計發展成為能夠平衡抗增殖藥物傳輸與複雜支架和聚合物技術的精密平台。這一發展得益於生物相容性、輸送能力和臨床療效的不斷改進，以及隨機試驗和真實世界註冊研究中持續不斷的證據生成。

臨床醫生和採購主管現在必須應對這樣一個情況：器械選擇會影響手術成功率、長期血管通暢性以及下游資源利用率。因此，了解器械設計、藥物動力學、聚合物行為和臨床適應症之間的相互作用，對於最佳化患者護理和機構績效至關重要。同時，監管監督和付款方需求正將重點轉向可證明的安全性和長期有效性，促使製造商強調上市後數據和差異化的臨床聲明。在此背景下，本摘要概述了醫院、門診中心和分銷通路相關人員決策時需要考慮的策略、臨床和商業性因素。

分析重新定義塗藥支架領域患者治療結果和市場動態的技術、臨床和商業性變革

技術、臨床和市場力量的融合正在再形成藥物釋放型支架的格局，這些力量共同推動著改變。材料科學的進步使得更薄的支架設計和更俱生物相容性的塗層成為可能，而這些硬體改進與藥物配方的創新相輔相成，旨在最佳化局部抗增殖效果，同時最大限度地降低全身暴露。因此，器械的差異化越來越依賴細微的性能特徵，例如內皮癒合特性、在複雜解剖結構中的輸送能力以及與輔助影像和生理評估工具的兼容性。

同時，臨床實踐也在不斷發展。外科醫生擴大將血管內成像和生理引導納入其常規工作流程，從而改變了器械選擇標準和手術方法。這種精準支架置入的趨勢為在影像引導下表現出可預測和可重複行為的支架平台提供了機會。從商業性角度來看，醫療保健系統越來越重視護理總成本和長期療效，從而凸顯了強力的上市後證據和基於價值的合約的重要性。此外，隨著專業創新者推出利基設計，而老牌製造商追求產品組合廣度和生命週期管理，競爭態勢正在加劇。監管預期也同樣不斷增強，更加重視長期安全數據和真實世界療效，促使製造商投資於縱向註冊和自適應試驗設計。總而言之，這些轉變正在重新定義臨床價值的展示方式、產品的採購方式以及公司如何優先安排其研發和上市活動。

2025 年美國關稅的詳細評估及其對供應鏈、籌資策略和藥物釋放型支架取得的影響

2025年美國加徵關稅可能會波及全球醫療設備供應鏈，對採購、庫存管理及籌資策略有具體影響。其初期影響將最顯著地體現在受關稅上調影響的跨境製造投入和成品器械上，促使採購機構重新評估其供應商佈局，並在成本、前置作業時間和供應商可靠性之間進行權衡。為此，一些醫療系統將擴大供應商基礎，優先考慮具有本地製造能力的供應商，或協商合約保護措施，以緩解短期價格波動。

在營運層面，醫療設備製造商和經銷商可能會重新評估其物流策略，強調替代路線、區域倉儲和多方採購，以維持供應的連續性。此類調整可能會導致更長的規劃週期和更高的營運成本，尤其是對於高價值植入式醫療設備而言。此外，採購團隊可能會調整其競標評估框架，將與關稅相關的成本差異和供應鏈彈性指標納入考量，從而改變那些成本基礎更容易受到關稅影響的供應商的競爭定位。

在臨床方面，相關人員必須確保採購變更不會損害器械品質或臨床療效。這需要嚴格的供應商資格確認、快速檢驗替代製造地，以及在醫院和門診中心層級謹慎管理器械過渡通訊協定。從創新角度來看，關稅可以增強本地生產和技術轉移的獎勵，加速對國內製造能力的投資以及向地區監管機構的備案。最終，雖然關稅可能會造成短期中斷和成本壓力，但它們也會催化策略轉變，影響製造商和醫療保健系統對韌性、供應商關係以及製造業地理分佈的思考。

細分洞察揭示了類型、藥物、應用、最終用戶和分銷細微差別如何影響臨床選擇、採購優先事項和商業化

藥物釋放型支架市場細分領域的差異化驅動著臨床決策和商業策略，而對支架類型、藥物、應用、最終用戶和分銷管道的綜合考慮對於理解其應用動態至關重要。就器械類型而言，市場分為聚合物塗層系統和非聚合物塗層平台。在聚合物塗層產品中，市場進一步細分為旨在隨時間推移吸收的可生物分解聚合物塗層設計和可長期保持塗層特性的耐用聚合物塗層結構。這些差異會影響癒合生物學、遠期不利事件概況以及向關注長期血管通暢性的臨床醫生訊息。

藥物選擇是另一個差異化因素，目前已有多種可用於洗脫藥物的設備，例如比奧莫司、Everolimus、紫杉醇和Sirolimus。每種藥物的藥理效力、組織滯留特性和先前依證均有所不同，這會影響針對特定病變類型和患者風險群的設備定位。冠狀動脈疾病的臨床需求和表現預期與周邊血管疾病不同，當操作人員處理複雜的周邊解剖結構或尋求持續改善肢體灌注時，設備屬性的權重也不同。

最終用戶也決定購買和使用模式。同時，門診手術中心優先考慮那些能夠提高效率、可預測結果和縮短工作流程的設備。最後，分銷管道決定了獲取和採購路徑。醫院藥局、線上藥局平台和零售藥局各自呈現出不同的路線、庫存和報銷考量，這些考量會影響設備如何到達照護現場。綜合起來，這些細分揭示了產品開發的重點、證據生成計劃和商業化策略，凸顯了製定能夠引起不同醫療環境中臨床醫生、供應鏈經理和付款人共鳴的客製化價值命題主張的必要性。

區域動態決定了不同醫療體系和經濟體中藥物釋放型支架的臨床採用、購買行為和報銷方式

區域動態對藥物釋放型支架的採用、報銷以及納入醫療路徑的方式有著重大影響，了解這些差異對於跨國策略和區域商業化計畫至關重要。在美洲，公立和私立支付機構的報銷框架各不相同，採購者在評估新的支架平台時通常會強調比較臨床數據和手術經濟學。採購週期可以集中在醫院網路內，也可以分散在各個機構之間，這些差異決定了製造商的價值主張以及供應協議的談判方式。

歐洲、中東和非洲地區的市場模式差異巨大，已開發國家和新興歐洲國家的監管環境、報銷時限和臨床實務模式有顯著差異。在該地區的許多司法管轄區，衛生技術評估結果和國家採購計劃在市場准入決策中發揮著重要作用，因此製造商必須考慮建立區域合作夥伴關係，以使臨床證據方案與付款方預期相符，並加快市場准入。

亞太地區介入手術的成長伴隨著多樣化的監管途徑和參差不齊的本地製造能力。一些市場優先考慮具成本效益的設備，並迅速採用能夠提升通量和療效的技術；而其他市場則強調國內產業的發展和在地化。在每個地區，臨床培訓、血管內成像的可用性以及醫院報銷結構之間的相互作用決定了設備的選擇以及新平台的採用速度。因此，在證據產生、定價和相關人員參與方面採取細緻入微的區域性方法，對於最大限度地提高臨床應用率並解決本地系統的限制至關重要。

臨床、監管和付款人變化背景下藥物釋放型支架開發和商業化公司的競爭狀況和策略重點

藥物釋放型支架公司之間的競爭動態取決於產品創新、證據產生以及展示永續臨床和經濟價值的能力。成熟的製造商通常利用廣泛的產品組合、全球監管批准和豐富的上市後資料集來保持領先地位，而專業的創新企業則專注於差異化的設計特徵和利基適應症，為臨床應用鋪平道路。那些在穩健的臨床計畫和有針對性的真實世界證據收集之間取得平衡的公司，往往能夠透過兼顧療效和長期安全性問題，更有效地影響購買決策。

對於尋求整合互補能力（例如設備工程、配方專業知識和區域市場准入）的公司而言，夥伴關係和策略聯盟正變得越來越重要。供應鏈彈性已成為核心策略重點，製造商正在實現生產基地多元化，檢驗關鍵零件的多個供應商，並投資於支援快速擴大規模的品質系統。從商業性角度來看，提供全面培訓、實施支援和數據主導提案主張的公司正日益受到注重流程一致性和最佳化結果的醫院系統的青睞。總而言之，為了保持競爭優勢，市場領導者和競爭者都必須使其研發投資、證據策略和供應鏈計畫與臨床醫生、醫療系統和付款人不斷變化的期望保持一致。

為領導者提供實用建議，以加速塗藥支架領域的創新、最佳化採購並改善臨床和商業性結果

產業領導者可以採取具體行動，加速創新，保障供應連續性，鞏固商業性地位，同時改善病患治療效果。首先，優先制定清晰的證據藍圖，將隨機臨床試驗和可操作的註冊庫結合起來，既能滿足監管要求，又能解決臨床醫生和付款人的實際擔憂。其次，投資於供應鏈多元化，包括區域製造能力和關鍵投入的有效二級供應商，將降低貿易中斷帶來的脆弱性，並支持與大型醫療系統進行更可預測的採購對話。

第三，將產品設計與影像引導介入和新興治療途徑的實際情況結合，將增強臨床差異化。在注重精準醫療的環境中，能夠清晰地促進血管內成像、可預測部署和一致癒合曲線的平台將更具吸引力。第四，製造商應擴展其商業模式，在可行的情況下納入基於價值的契約試點和與結果掛鉤的契約，從而與衛生系統的優先事項更加緊密地協調一致。最後，臨床醫生教育和應用支援，例如程序培訓和數據共用計劃，可以提高採用率並最佳化實際應用效果。透過以整合的方式實施這些措施，產業領導者可以平衡當前的業務挑戰和長期創新目標。

調查方法，總結了臨床文獻綜合、專家相關人員參與、數據檢驗和藥物釋放型支架研究中使用的分析技術。

該報告的研究結果基於一種多方法調查方法，該方法整合了臨床文獻、專家相關人員的見解和檢驗的數據來源。分析過程始於對同行評審的臨床研究、指南文件和監管文件進行系統性回顧，以建立支架技術的臨床性能基準。除了次要分析之外，我們還與介入性心臟病專家、血管專家、採購負責人和分銷合作夥伴進行了結構化訪談和諮詢，以了解該領域對器械選擇、操作流程和供應鏈約束的觀點。

原始資料收集包括有針對性的定性訪談和去識別化程序登記冊的審查，以檢驗文獻中觀察到的模式。透過將臨床結果與相關人員的回饋和操作考量進行交叉引用，進行資料三角測量和檢驗，並透過記錄納入標準、訪談通訊協定和資料清理流程來保持調查方法透明度。在適用的情況下，結果會根據法律規範和報銷慣例進行具體分析，以確保所提供的見解既能反映臨床實際情況，又能反映商業性需求。

結論性綜合報告強調了策略重點、創新需求以及改善病患治療效果和醫療產業復原力的協作行動

綜上所述，藥物釋放型支架領域正處於曲折點，其驅動力來自材料科學的進步、臨床實踐的演變以及商業性預期的不斷變化。持續的差異化將取決於此器材平台能否展現出具有臨床意義的改進，同時又能適應現代介入治療的程序性現實。同時，貿易政策的變化以及對彈性供應鏈的需求等外部壓力將影響採購行為和產品供應，這給製造商和醫療保健系統帶來了挑戰和策略機會。

為了應對這種環境，相關人員必須採取一種協作的方式，將強大的證據生成、營運韌性和周到的商業化相結合。臨床領導者應繼續採用影像引導和生理主導的實踐，採購團隊應將供應鏈風險納入採購框架，製造商應追求以令人信服的真實世界數據為支撐的重點創新。這種整體方向將有助於確保設備技術的進步轉化為患者照護的持續改善，並為醫療保健系統帶來持久的價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 可生物分解聚合物藥物釋放型支架的出現降低了晚期支架血栓症的風險
  • 擴大採用光學同調斷層掃描進行血管內影像引導，以最佳化藥物釋放型支架的放置
  • 過渡到超薄支柱藥物釋放型支架可提高輸送能力並減少放置後的動脈創傷。
  • 採用微儲庫技術控制釋放抗增殖藥物的無聚合物藥物釋放型支架的出現
  • 由於心血管疾病盛行率上升和保險報銷範圍擴大，亞太地區和拉丁美洲的需求正在增加。
  • 醫療設備製造商與生物製藥公司合作開發下一代整合平台
  • 重視長期真實世界證據研究，檢驗第二代藥物釋放型支架的安全性和有效性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章藥物釋放型支架市場（按類型）

  • 聚合物塗層
    • 可生物分解聚合物塗層
    • 耐用的聚合物塗層
  • 不含聚合物

第9章藥物釋放型支架市場（按藥物）

  • Biolimus洗脫
  • Everolimus洗脫
  • 紫杉醇洗脫
  • Sirolimus洗脫

第 10 章藥物釋放型支架市場（依應用）

  • 冠狀動脈疾病
  • 周圍血管疾病

第 11 章藥物釋放型支架市場（依最終用戶）

  • 門診手術中心
  • 醫院

第12章藥物釋放型支架市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第13章藥物釋放型支架市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章藥物釋放型支架市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章藥物釋放型支架市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • BIOTRONIK AG
    • MicroPort Scientific Corporation
    • Lepu Medical Technology（Beijing）Co., Ltd.
    • Meril Life Sciences Private Limited
    • Biosensors International Group, Ltd.
    • Johnson & Johnson
Product Code: MRR-807A20B5CCC6

The Drug Eluting Stent Market is projected to grow by USD 18.76 billion at a CAGR of 11.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.05 billion
Estimated Year [2025] USD 8.93 billion
Forecast Year [2032] USD 18.76 billion
CAGR (%) 11.15%

Comprehensive introduction outlining clinical relevance, device evolution, regulatory pathways, and strategic imperatives shaping adoption of drug eluting stents

Drug eluting stents have become a pivotal therapeutic intervention in interventional cardiology and vascular medicine, embedding themselves within modern treatment pathways for a range of atherosclerotic conditions. Over the past two decades, these devices have evolved from first-generation designs into sophisticated platforms that balance antiproliferative drug delivery with refined scaffold and polymer technology. This evolution has been driven by iterative improvements in biocompatibility, deliverability, and clinical outcomes, and by a continuous cycle of evidence generation across randomized trials and real-world registries.

Clinicians and procurement leaders now must navigate a landscape in which device choice influences procedural success, long-term vessel patency, and downstream resource utilization. As such, understanding the interplay of device design, drug kinetics, polymer behavior, and clinical indication is central to optimizing patient care and institutional performance. Simultaneously, regulatory scrutiny and payer requirements have shifted priorities toward demonstrable safety and long-term effectiveness, prompting manufacturers to emphasize post-market data and differentiated clinical claims. In this context, the present summary frames the strategic, clinical, and commercial considerations that underpin decision making for stakeholders across hospitals, ambulatory centers, and distribution channels.

Analysis of transformative technological, clinical, and commercial shifts redefining patient outcomes and market dynamics within the drug eluting stent landscape

The drug eluting stent landscape is being reshaped by converging technological, clinical, and market forces that together constitute transformative change. Advances in materials science have enabled thinner strut designs and more biocompatible coatings, and these hardware refinements are complemented by innovations in drug formulation that aim to optimize local antiproliferative effects while minimizing systemic exposure. As a result, device differentiation increasingly rests on nuanced performance characteristics such as endothelial healing profiles, deliverability in complex anatomies, and compatibility with adjunctive imaging and physiologic assessment tools.

Concurrently, clinical practice is evolving: operators are integrating intravascular imaging and physiologic guidance into routine workflows, which alters device selection criteria and procedural approaches. This trend toward precision deployment is creating opportunities for stent platforms that demonstrate predictable and reproducible behavior under image-guided techniques. From a commercial perspective, healthcare systems are emphasizing total cost of care and long-term outcomes, which elevates the importance of robust post-market evidence and value-based contracting. Additionally, the competitive dynamic is intensifying as specialized innovators introduce niche designs while established manufacturers pursue portfolio breadth and lifecycle management. Regulatory expectations have likewise become more rigorous, with stronger emphasis on longer-term safety data and real-world performance, prompting manufacturers to invest in longitudinal registries and adaptive study designs. Taken together, these shifts are redefining how clinical value is demonstrated, how products are procured, and how companies prioritize R&D and market access activities.

In-depth assessment of United States tariff actions in 2025 and their effects on supply chains, procurement strategies, and access to drug eluting stents

The imposition of United States tariff measures in 2025 has the potential to reverberate across global supply chains for medical devices, creating tangible implications for procurement, inventory management, and sourcing strategies. Early effects are most pronounced where manufacturing inputs or finished devices cross borders subject to increased duties, prompting purchasing organizations to reassess supplier footprints and to evaluate the tradeoffs between cost, lead time, and supplier reliability. In response, some health systems may broaden their supplier base, prioritize vendors with local manufacturing capabilities, or negotiate contractual protections to mitigate short-term price volatility.

At the operational level, device manufacturers and distributors are likely to revisit logistics strategies, increasing the emphasis on alternative routing, regional warehousing, and multi-sourcing to preserve continuity of supply. These adjustments can lengthen planning cycles and raise working capital requirements, particularly for high-value implantable devices. Moreover, procurement teams may adjust tender evaluation frameworks to incorporate duty-related cost differentials and supply chain resilience metrics, thereby altering competitive positioning for suppliers whose cost base is sensitive to tariff exposure.

Clinically, stakeholders will need to ensure that any shifts in sourcing do not compromise device quality or clinical outcomes. This necessitates rigorous supplier qualification, accelerated validation of alternative manufacturing sites, and careful management of device transition protocols at the hospital and ambulatory center level. From an innovation standpoint, tariffs can increase incentives for local production and technology transfer, potentially accelerating investments in domestic manufacturing capacity and in-region regulatory submissions. Ultimately, while tariffs may create near-term disruption and cost pressure, they also catalyze strategic shifts that influence how manufacturers and health systems think about resilience, supplier relationships, and geographic diversification of manufacturing.

Segmentation insights revealing how type, drug, application, end user, and distribution nuances drive clinical choice, procurement priorities, and commercialization

Segment-level differentiation in the drug eluting stent space drives both clinical decision making and commercial strategy, and an integrated view of type, drug, application, end user, and distribution channel is essential to appreciate adoption dynamics. Regarding device type, the market distinguishes between polymer coated systems and polymer free platforms; within polymer coated offerings, there is a further split between biodegradable polymer coated designs that aim to resorb over time and durable polymer coated constructs that retain their coating profile long term. These distinctions influence healing biology, late adverse event profiles, and messaging for clinicians focused on long-term vessel patency.

Drug selection represents another axis of differentiation, with devices eluting agents such as biolimus, everolimus, paclitaxel, and sirolimus. Each drug differs in pharmacologic potency, tissue retention characteristics, and historical evidence base, which affects device positioning for specific lesion types and patient risk cohorts. Application context matters as well: the clinical needs and performance expectations for coronary artery disease differ from those for peripheral vascular disease, and device attributes are weighed differently when operators manage challenging peripheral anatomies or seek durable improvement in limb perfusion.

End users also frame purchasing and utilization patterns. Hospitals typically drive higher procedural volumes and manage complex cases requiring a broad set of device options and rapid supply availability, whereas ambulatory surgical centers focus on efficiency, predictable outcomes, and devices that facilitate short-stay workflows. Finally, distribution channels shape access and procurement pathways: hospital pharmacies, online pharmacy platforms, and retail pharmacies each present distinct routing, inventory, and reimbursement considerations that affect how devices reach point-of-care. Taken together, these segmentation dimensions inform product development priorities, evidence generation plans, and commercialization strategies, and they underscore the need for tailored value propositions that resonate with clinicians, supply chain managers, and payers across diverse care settings.

Regional dynamics that determine clinical adoption, purchasing behavior, and reimbursement approaches for drug eluting stents across diverse healthcare systems and economies

Regional dynamics materially influence how drug eluting stents are adopted, reimbursed, and integrated into care pathways, and understanding these differences is critical for multinational strategy and for localized commercialization plans. In the Americas, reimbursement frameworks vary across public and private payers, and purchasers often emphasize comparative clinical data and procedural economics when evaluating new stent platforms. Procurement cycles can be centralized within hospital networks or decentralized across individual institutions, and this variability shapes how manufacturers present value and negotiate supply agreements.

Across Europe, Middle East & Africa the landscape is heterogeneous, with regulatory processes, reimbursement timelines, and clinical practice patterns differing significantly between advanced European markets and emerging economies. In many jurisdictions within this region, health technology assessment outcomes and national procurement programs play an outsized role in determining market access, which requires manufacturers to align clinical evidence packages with payer expectations and to consider regional partnerships to expedite market entry.

In Asia-Pacific, growth in interventional procedures is accompanied by diverse regulatory pathways and varying levels of local manufacturing capability. Some markets prioritize cost-effective devices and demonstrate rapid adoption of technologies that deliver demonstrable improvements in throughput and outcomes, whereas others emphasize domestic industry development and localization. Across all regions, the interplay of clinical training, availability of intravascular imaging, and the structure of hospital reimbursement shapes device selection and the pace at which new platforms gain traction. Therefore, a regionally nuanced approach to evidence generation, pricing, and stakeholder engagement is essential to maximize clinical uptake and to address local system constraints.

Competitive profiles and strategic priorities for companies developing and commercializing drug eluting stents amid clinical, regulatory, and payer shifts

Competitive dynamics among companies engaged with drug eluting stents are defined by product innovation, evidence generation, and the ability to demonstrate sustainable clinical and economic value. Established manufacturers typically leverage broad portfolios, global regulatory clearances, and extensive post-market datasets to maintain leadership, while specialized innovators focus on differentiated design features or niche indications to create pathways for clinical adoption. Firms that balance robust clinical programs with targeted real-world evidence collection tend to influence purchasing decisions more effectively because they can address both efficacy and longer-term safety concerns.

Partnerships and strategic alliances are increasingly important as companies seek to combine complementary capabilities, such as device engineering, drug formulation expertise, and regional market access. Supply chain resilience has become a core strategic priority, prompting manufacturers to diversify production footprints, validate multiple suppliers for critical components, and invest in quality systems that support rapid scaling. Commercially, companies that offer comprehensive training, implementation support, and data-driven value propositions find greater receptivity among hospital systems focused on procedural consistency and outcome optimization. In sum, market leaders and challengers alike must align R&D investments, evidence strategies, and supply chain planning with the shifting expectations of clinicians, health systems, and payers to sustain competitive advantage.

Practical recommendations for leaders to accelerate innovation, optimize procurement, and improve clinical and commercial outcomes in the drug eluting stent space

Industry leaders can take concrete actions to accelerate innovation, safeguard supply continuity, and strengthen commercial positioning while improving patient outcomes. First, prioritizing a clear evidence roadmap that couples randomized clinical studies with pragmatic registries will address both regulatory requirements and the practical concerns of clinicians and payers. Second, investing in supply chain diversification, including regional manufacturing capabilities and validated secondary suppliers for critical inputs, will reduce vulnerability to trade disruptions and support more predictable procurement conversations with large health systems.

Third, aligning product design with the realities of image-guided intervention and emerging care pathways will enhance clinical differentiation; platforms that demonstrably facilitate intravascular imaging, predictable deployment, and consistent healing profiles will be more attractive in settings that demand precision. Fourth, manufacturers should expand commercial models to include value-based contracting pilots and outcome-linked agreements where feasible, enabling closer alignment with health system priorities. Finally, advancing clinician education and deployment support, including procedural training and data-sharing initiatives, will improve uptake and optimize real-world performance. By executing these measures in an integrated manner, industry leaders can balance immediate operational challenges with longer term innovation goals.

Methodology summarizing clinical literature synthesis, expert stakeholder engagement, data validation, and analytical techniques used in drug eluting stent studies

This report's findings are rooted in a multi-method research approach that synthesizes clinical literature, expert stakeholder insights, and validated data sources. The analytical process began with systematic reviews of peer-reviewed clinical studies, guideline documents, and regulatory submissions to establish the clinical performance benchmarks for stent technologies. These secondary-source analyses were complemented by structured interviews and consultations with interventional cardiologists, vascular specialists, procurement leaders, and distribution partners to capture frontline perspectives on device selection, procedural workflow, and supply chain constraints.

Primary data collection included targeted qualitative interviews and the review of anonymized procedural registries to validate patterns observed in the literature. Data triangulation and validation were performed through cross-referencing clinical outcomes with stakeholder feedback and operational considerations, and methodological transparency was maintained by documenting inclusion criteria, interview protocols, and data-cleaning processes. Wherever applicable, results were contextualized against regulatory frameworks and reimbursement practices to ensure that the insights provided reflect both clinical realities and commercial imperatives.

Concluding synthesis stressing strategic priorities, innovation imperatives, and coordinated actions to improve patient outcomes and sector resilience

In synthesis, the drug eluting stent domain is at an inflection point driven by material science advances, evolving clinical practice, and shifting commercial expectations. Continued differentiation will depend on the ability of device platforms to demonstrate clinically meaningful improvements while fitting into the procedural realities of modern interventional practice. At the same time, external pressures such as trade policy changes and the demand for resilient supply chains will influence procurement behavior and product availability, creating both challenges and strategic opportunities for manufacturers and health systems.

To navigate this environment, stakeholders must adopt a coordinated approach that marries robust evidence generation with operational resilience and thoughtful commercialization. Clinical leaders should continue to embrace image-guided and physiology-driven practices, procurement teams must incorporate supply chain risk into purchasing frameworks, and manufacturers need to pursue focused innovation supported by compelling real-world data. This holistic orientation will help ensure that advances in device technology translate into sustained improvements in patient care and durable value for healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of biodegradable polymer drug eluting stents reducing late stent thrombosis risk
  • 5.2. Increasing adoption of intravascular imaging guidance with optical coherence tomography to optimize drug eluting stent placement
  • 5.3. Shift toward ultrathin strut drug eluting stents enhancing deliverability and reducing arterial injury post implantation
  • 5.4. Emergence of polymer free drug eluting stents with microreservoir technology for controlled antiproliferative drug release
  • 5.5. Growing demand in Asia Pacific and Latin America driven by rising cardiovascular disease prevalence and expanded reimbursement
  • 5.6. Collaboration between medical device manufacturers and biopharmaceutical companies for next generation combination drug eluting stent platforms
  • 5.7. Escalating focus on long term real world evidence studies to validate safety and efficacy of second generation drug eluting stents

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Stent Market, by Type

  • 8.1. Polymer Coated
    • 8.1.1. Biodegradable Polymer Coated
    • 8.1.2. Durable Polymer Coated
  • 8.2. Polymer Free

9. Drug Eluting Stent Market, by Drug

  • 9.1. Biolimus Eluting
  • 9.2. Everolimus Eluting
  • 9.3. Paclitaxel Eluting
  • 9.4. Sirolimus Eluting

10. Drug Eluting Stent Market, by Application

  • 10.1. Coronary Artery Disease
  • 10.2. Peripheral Vascular Disease

11. Drug Eluting Stent Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Drug Eluting Stent Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Drug Eluting Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Eluting Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Eluting Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Boston Scientific Corporation
    • 16.3.3. Medtronic plc
    • 16.3.4. Terumo Corporation
    • 16.3.5. BIOTRONIK AG
    • 16.3.6. MicroPort Scientific Corporation
    • 16.3.7. Lepu Medical Technology (Beijing) Co., Ltd.
    • 16.3.8. Meril Life Sciences Private Limited
    • 16.3.9. Biosensors International Group, Ltd.
    • 16.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG ELUTING STENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 242. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 243. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 244. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 245. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 284. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 285. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 286. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 287. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 298. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 299. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 300. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 301. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. CANADA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. CANADA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 324. CANADA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 325. CANADA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 326. CANADA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. CANADA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. CANADA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. CANADA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. MEXICO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. MEXICO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. MEXICO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2024 (USD MILLION)
  • TABLE 336. MEXICO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2025-2032 (USD MILLION)
  • TABLE 337. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
  • TABLE 338. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025-2032 (USD MILLION)
  • TABLE 339. MEXICO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. MEXICO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. MEXICO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. MEXICO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. MEXICO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. MEXICO DRUG E